Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mitsubishi Tanabe Pharma America to Present Analysis of Real-World Claims Data for Patients Treated With RADICAVA® (edaravone) During 2021 European Network to Cure ALS (ENCALS) Virtual Meeting | ||
By: PR Newswire Association LLC. - 12 May 2021 | Back to overview list |
|
JERSEY CITY, N.J., May 12, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS). The analysis will be presented during the 2021 European Network to Cure ALS (ENCALS) Meeting, being held virtually May 12-14. "Initial insights shared with the scientific community during ENCALS are a part of our wide-ranging efforts to compile real-world data that can be used to learn as much as possible about the clinical experience of RADICAVA," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "We utilized a rigorous statistical methodology to comprehensively assess more than two years of administrative claims data for our therapy. Analysis is still ongoing, and we look forward to sharing more details about the methodology and findings with the ALS scientific community." The analysis, funded and conducted by MTPA, utilized a real-world de-identified database of administrative health claims across the U.S. to evaluate data on overall survival among commercially insured ALS patients treated with RADICAVA, compared to a control group of patients not prescribed the product. Utilizing 1:2 propensity score matching, the analysis compared 635 non-RADICAVA-treated control patients with 319 patients who initiated RADICAVA treatment between August 8, 2017 and June 30, 2019. Details about the findings will be shared at ENCALS. MTPA will be conducting further analysis of this real-world data with plans to submit the full results for publication in a peer-reviewed journal. While a randomized controlled clinical trial evaluating overall survival has not been conducted, the findings from this data provide important insights. The company also will continue to explore real-world experience through additional research. About RADICAVA® (edaravone) INDICATION IMPORTANT SAFETY INFORMATION
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of RADICAVA?
The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache. These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information, including full Prescribing Information and Patient Information, please visit www.RADICAVA.com. About Mitsubishi Tanabe Pharma America, Inc. Overview of Mitsubishi Tanabe Pharma Corporation Media Inquiries: 1 RADICAVA® (edaravone) U.S. Prescribing Information. March 2021. View original content to download multimedia:http://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-analysis-of-real-world-claims-data-for-patients-treated-with-radicava-edaravone-during-2021-european-network-to-cure-als-encals-virtual-meeting-301290179.html SOURCE Mitsubishi Tanabe Pharma America, Inc. |
||
|
||
Copyright 2021 PR Newswire Association LLC. | Back to overview list |